

**The Indian Journal of Dermatology,
Venereology and Leprology (IJDVL)**

is a bimonthly publication of the Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) and is published for IADVL by Medknow Publications.

The Journal is **indexed/listed** with Science Citation Index Expanded, PUBMED, EMBASE, Bioline International, CAB Abstracts, Global Health, DOAJ, Health and Wellness Research Center, SCOPUS, Health Reference Center Academic, InfoTrac One File, Expanded Academic ASAP, NIWI, INIST, Uncover, JADE (Journal Article Database), IndMed, Indian Science Abstract's and PubList.

All the rights are reserved. Apart from any fair dealing for the purposes of research or private study, or criticism or review, no part of the publication can be reproduced, stored, or transmitted, in any form or by any means, without the prior permission of the Editor, IJDVL.

The information and opinions presented in the Journal reflect the views of the authors and not of the IJDVL or its Editorial Board or the IADVL. Publication does not constitute endorsement by the journal.

The IJDVL and/or its publisher cannot be held responsible for errors or for any consequences arising from the use of the information contained in this journal.

The appearance of advertising or product information in the various sections in the journal does not constitute an endorsement or approval by the journal and/or its publisher of the quality or value of the said product or of claims made for it by its manufacturer.

The journal is published and distributed by Medknow Publications. Copies are sent to subscribers directly from the publisher's address. It is illegal to acquire copies from any other source. If a copy is received for personal use as a member of the association/society, one can not resale or give-away the copy for commercial or library use.

The Journal is printed on acid free paper.

EDITOR

Uday Khopkar

ASSOCIATE EDITORS

Ameet Valia Sangeeta Amladi

ASSISTANT EDITORS

K. C. Nischal Sushil Pande Vishalakshi Viswanath

EDITORIAL BOARD

Chetan Oberai (Ex-officio)	Koushik Lahiri (Ex-officio)	Sanjeev Handa
Arun Inamdar	Joseph Sundharam	S. L. Wadhwa
Binod Khaitan	Kanthraj GR	Sharad Mutalik
D. A. Satish	M. Ramam	Shruthakirti Sheno
D. M. Thappa	Manas Chatterjee	Susmit Halder
H. R. Jerajani	Rajeev Sharma	Venkatram Mysore
	Sandipan Dhar	

EDITORIAL ADVISORY BOARD

Aditya Gupta, Canada	Jag Bhawan, USA
C. R. Srinivas, India	John McGrath, UK
Celia Moss, UK	K. Pavithran, India
Giam Yoke Chin, Singapore	R. G. Valia, India
Gurmohan Singh, India	Robert A. Schwartz, USA
Howard Libman, USA	Robin Graham-Brown, UK
J. S. Pasricha, India	V. N. Sehgal, India
Rodney Sinclair, Australia	

STATISTICAL EDITOR

S. R. Suryawanshi

OMBUDSMAN

A. K. Bajaj

IADVL NATIONAL EXECUTIVE 2006 – 2007

President

Chetan M. Oberai

Immediate Past President

Suresh Joshipura

President (Elect)

S. Sacchidanand

Vice-Presidents

Amrinder Jit Kanwar

Dilip Shah

Secretary

Koushik Lahiri

Treasurer

Arijit Coondoo

Jt. Secretaries

Rakesh Bansal

Manas Chatterjee

EDITORIAL OFFICE

Dr. Uday Khopkar

Editor, IJDVL, Department of Dermatology,
117, 1st Floor, Old OPD Building, K.E.M.
Hospital, Parel, Mumbai - 400012, India.
E-mail: editor@ijdvil.com

Published for IADVL by

MEDKNOW PUBLICATIONS

A-109, Kanara Business Centre, Off Link Road,
Ghatkopar (E), Mumbai - 400075, India.
Tel: 91-22-6649 1818 / 1816
Website: www.medknow.com

Indian Journal of Dermatology, Venereology & Leprology

Journal indexed with SCI-E, PubMed, and EMBASE

Vol 74 | Issue 1 | Jan-Feb 2008

C O N T E N T S

EDITORIAL REPORT - 2007

JDVL gets into the Science Citation Index Expanded!

Uday Khopkar 1

EDITORIAL

Registration and reporting of clinical trials

Uday Khopkar, Sushil Pande 2

SPECIALTY INTERFACE

Preventing steroid induced osteoporosis

Jyotsna Oak 5

REVIEW ARTICLE

Molecular diagnostics in genodermatoses - simplified

Ravi N. Hiremagalore, Nagendrachary Nizamabad, Vijayaraghavan Kamasamudram 8

ORIGINAL ARTICLES

A clinicoepidemiological study of polymorphic light eruption

Lata Sharma, A. Basnet 15

A clinico-epidemiological study of PLE was done for a period of one year to include 220 cases of PLE of skin type between IV and VI. The manifestation of PLE was most common in house wives on sun exposed areas. Most of the patients of PLE presented with mild symptoms and rash around neck, lower forearms and arms which was aggravated on exposure to sunlight. PLE was more prevalent in the months of March and September and the disease was recurrent in 31.36% of cases.

Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: A randomized, double-blind, multicentric study

Anil Pareek, Uday Khopkar, S. Sacchidanand, Nitin Chandurkar, Geeta S. Naik 18

In a double-blind randomized, comparative multicentric study evaluating efficacy of antimalarials in polymorphic light eruption, a total of 117 patients of PLE were randomized to receive hydroxychloroquine and chloroquine tablets for a period of 2 months (initial twice daily dose was reduced to once daily after 1 month). A significant reduction in severity scores for burning, itching, and erythema was observed in patients treated with hydroxychloroquine as compared to chloroquine. Hydroxychloroquine was found to be a safe antimalarial in the dosage studied with lesser risk of ocular toxicity.

Many faces of cutaneous leishmaniasis

Arfan Ul Bari, Simeen Ber Rahman

Symptomatic cutaneous leishmaniasis is diverse in its presentation and outcome in a tropical country like Pakistan where the disease is endemic. The study describes the clinical profile and atypical presentations in 41 cases among 718 patients of cutaneous leishmaniasis. Extremity was the most common site of involvement and lupoid cutaneous leishmaniasis was the most common atypical form observed. Authors suggest that clustering of atypical cases in a geographically restricted region could possibly be due to emergence of a new parasite strain.



23

Forehead plaque: A cutaneous marker of CNS involvement in tuberous sclerosis

G. Raghu Rama Rao, P. V. Krishna Rao, K. V. T. Gopal, Y. Hari Kishan Kumar, B. V. Ramachandra

In a retrospective study of 15 patients of tuberous sclerosis, eight patients had central nervous system involvement. Among these 8 cases, 7 cases had forehead plaque. This small study suggests that presence of forehead plaque is significantly associated with CNS involvement.




28

BRIEF REPORTS

Ligand-binding prediction for ErbB2, a key molecule in the pathogenesis of leprosy

Viroj Wiwanitkit.....



32

SCORTEN: Does it need modification?

Col. S. S. Vaishampayan, Col. A. L. Das, Col. R. Verma

35

CASE REPORTS

Universal acquired melanosis (Carbon baby)

P. K. Kaviarasan, P. V. S. Prasad, J. M. Joe, N. Nandana, P. Viswanathan



38

Adult onset, hypopigmented solitary mastocytoma: Report of two cases


D. Pandhi, A. Singal, S. Aggarwal.....



41

Incidental finding of skin deposits of corticosteroids without associated granulomatous inflammation: Report of three cases

Rajiv Joshi



44

Erythromelanosus follicularis faciei et colli: Relationship with keratosis pilaris

M. Augustine, E. Jayaseelan



47

Naxos disease: A rare occurrence of cardiomyopathy with woolly hair and palmoplantar keratoderma

R. Rai, B. Ramachandran, V. S. Sundaram, G. Rajendren, C. R. Srinivas



50

Granular parakeratosis presenting with facial keratotic papules

R. Joshi, A. Taneja



53

Adult cutaneous myofibroma

V. Patel, V. Kharkar, U. Khopkar



56

LETTERS TO THE EDITOR

Extragenital lichen sclerosus of childhood presenting as erythematous patches

N. G. Stavrianeas, A. C. Katoulis, A. I. Kanelleas, E. Bozi, E. Toumbis-Ioannou



59

Leukocytoclastic vasculitis during pegylated interferon and ribavirin treatment of hepatitis C virus infection

Esra Adisen, Murat Dizbay, Kenan Hize, Nilsel İlter

60

Poland's syndrome

Saurabh Agarwal, Ajay Arya..... 62

Hereditary leiomyomatosis with renal cell carcinoma

Sachin S. Soni, Swarnalata Gowrishankar, Gopal Kishan Adikey,
Anuradha S. Raman 63

Infantile onset of Cockayne syndrome in two siblings

Prerna Batra, Abhijeet Saha, Ashok Kumar 65

Multiple xanthogranulomas in an adult

Surajit Nayak, Basanti Acharjya, Basanti Devi, Manoj Kumar Patra 67



Bullous pyoderma gangrenosum associated with ulcerative colitis

Naik Chandra Lal, Singh Gurcharan, Kumar Lekshman, Lokanatha K..... 68



Sporotrichoid pattern of malignant melanoma

Ranjan C. Rawal, Kanu Mangla..... 70



Acitretin for Papillon-Lefèvre syndrome in a five-year-old girl

Didem Didar Balci, Gamze Serarslan, Ozlem Sangun, Seydo Homan 71

Bilateral Becker's nevi

Ramesh Bansal, Rajeev Sen..... 73



RESIDENTS' PAGE

Madarosis: A dermatological marker

Silonie Sachdeva, Pawan Prasher 74

FOCUS

Botulinum toxin

Preeti Savardekar 77

E-IDVL

Net Studies

A study of oxidative stress in paucibacillary and multibacillary leprosy

P. Jyothi, Najeeba Riyaz, G. Nandakumar, M. P. Binitha 80

Clinical study of cutaneous drug eruptions in 200 patients

M. Patel Raksha, Y. S. Marfatia 80

Net case

Porokeratosis confined to the genital area: A report of three cases

Sujata Sengupta, Jayanta Kumar Das, Asok Gangopadhyay 80

Net Letters

Camisa disease: A rare variant of Vohwinkel's syndrome

T. S. Rajashekar, Gurcharan Singh, Chandra Naik, L. Rajendra Okade 81

Cross reaction between two azoles used for different indications

Arika Bansal, Rashmi Kumari, M. Ramam 81

Net Quiz

Asymptomatic erythematous plaque on eyelid

Neeraj Srivastava, Lakhan Singh Solanki, Sanjay Singh 82



QUIZ

A bluish nodule on the arm

Ragunatha S., Arun C. Inamadar, Vamseedhar Annam, B. R. Yelikar 83



REFEREE INDEX-2007

INSTRUCTIONS FOR AUTHORS

The copies of the journal to members of the association are sent by ordinary post. The editorial board, association or publisher will not be responsible for non-receipt of copies. If any of the members wish to receive the copies by registered post or courier, kindly contact the journal's / publisher's office. If a copy returns due to incomplete, incorrect or changed address of a member on two consecutive occasions, the names of such members will be deleted from the mailing list of the journal. Providing complete, correct and up-to-date address is the responsibility of the members. Copies are sent to subscribers and members directly from the publisher's address; it is illegal to acquire copies from any other source. If a copy is received for personal use as a member of the association/society, one cannot resale or give-away the copy for commercial or library use.

SCORTEN: Does it need modification?

Col. S. S. Vaishampayan, Col. A. L. Das, Col. R. Verma

Department of Dermatology, Armed Forces Medical College and Command Hospital (SC), Pune, Maharashtra, India

Address for correspondence: Dr. (Col) S. Vaishampayan, Dermatologist, 155 Base Hospital c/o 99 APO. E-mail: sanjeevssv1@yahoo.co.in

ABSTRACT

Background: Toxic epidermal necrolysis (TEN) is a drug induced acute life threatening condition with mortality ranging from about 15 to 60%. A 'severity of illness' score termed as SCORTEN has been developed to predict mortality in TEN cases at the time of admission. It is calculated by giving one point for each of predetermined seven variables, evaluated during first 24 hours of admission. Total score ranging from 1-7 predicts a probability of mortality from 0.03 to 0.90. **Aim:** A prospective study was conducted to analyze efficacy of 'SCORTEN' in TEN cases to predict mortality during their management. **Methods:** All cases of TEN reporting for management to the hospital were assessed using 'SCORTEN' on day one and day five to predict probable mortality, this data was then compared with ultimate outcome. **Results:** During the study period, we treated 10 cases of TEN, all induced by drugs, patient's age ranging from 03 to 70 years and body surface area (BSA) involvement from 10 to 95%. Three cases succumbed to death. These cases were analyzed with SCORTEN to predict probability of mortality at the time of admission and day five. We encountered some variations from the original study. It was observed that if patients are analyzed with SCORTEN on a daily/alternate day basis, it will serve as a better predictor of mortality. **Conclusion:** Body surface area (BSA) involvement and age probably need more weightage in calculations. Besides malignancy, tuberculosis and pre-existing diabetes also need to be included while predicting mortality.

Key Words: Toxic epidermal necrolysis, SCORTEN, Predictors of mortality

INTRODUCTION

Toxic epidermal necrolysis (TEN) is a drug related, acute life threatening dermatological disease. Apoptosis of cells causes erosion of mucous membranes, extensive detachment of epidermis and severe constitutional symptoms. Stevens-Johnson syndrome (SJS) and TEN are considered variants within a continuous spectrum, SJS or SJS-TEN overlaps being milder forms. This classification is based on percentage of denuded skin.^[1]

The incidence of TEN is reported to be 0.4-2 cases per million populations per year.^[2] In India exact incidence of this near fatal disease is not known and seems to be increasing due to indiscriminate use of drugs. This severe disease is reported to have a mortality rate ranging from 15 to 40% with frequent disability in survivors. Various prognostic factors already known are advancing age, maximal body surface area (BSA) detachment and increased blood urea levels.^[3]

Another major cause of death in TEN has been reported to be bronchial epithelial detachment.

There are several severity-of-illness scores being used in ICUs to estimate the probability of hospital mortality. Specific scores have been developed for burn patients (age plus percentage of BSA burned) since general ICU scores can not be extrapolated on them and so is the case of acute dermatoses like TEN. A score termed as SCORTEN was developed by Basutji-Gatin *et al.* in year 2000, as a severity-of-illness score for TEN.^[4] It is a validated predictor of mortality in TEN patients when seen at the time of admission. The score is calculated by giving 01 point for each of the following 07 clinical variables during the first 24 hours of evaluation;

- Age more than 40 years
- Malignancy
- Heart rate >120/minute
- Initial epidermal detachment >10% of BSA
- Serum urea level >28 mgm/dl (40 mgm/dl in Indian settings)

How to cite this article: Vaishampayan SS, Das AL, Verma R. SCORTEN: Does it need modification? Indian J Dermatol Venereol Leprol 2008;74:35-7.

Received: November, 2006. **Accepted:** June, 2007. **Sources of support:** Nil, **Conflict of interest:** None declared.

- Serum glucose levels >250 mgm/dl and
- Serum bicarbonate levels <20 mEq/dl.

The probability of death predicted by this score is as follows: 0-1 points- 0.03; 2 points- 0.12; 3 points- 0.35; 4 points- 0.58; 5 to 7 points- 0.90. A probability of 0.90 means approximate 90 of 100 patients with TEN are expected to die. SCORTEN has been used extensively in large number of studies with good to excellent accuracy in predicting death in TEN cases. Since this score is relatively new, a study was conducted to find out applicability of SCORTEN in TEN patients in Indian settings.

METHODS

A prospective study was carried out at Command Hospital, Pune for 24 months. A total of 10 cases were diagnosed to have TEN/ SJS-TEN out of nearly 23000 cases seen in OPD during the study period. All the cases diagnosed to have TEN, were subjected to a standard battery of ICU protocol of investigations on day one, following which each case was analyzed using SCORTEN. Same battery of tests and analysis were also carried out on day

five and prediction of mortality on both days as predicted by SCORTEN was later compared with final outcome.

RESULTS

Since total number of patients was only 10 statistical analysis could not be done. We treated 10 cases of TEN with age ranging from 03 to 70 years and BSA involvement being 15 to almost 100%. Anticonvulsants were the commonest (5/10) drugs implicated, anti-tuberculous therapy being the next (2/10) common causative drug category. Paracetamol was thought to be the precipitating cause of TEN in one case. Many patients were on multiple drugs.

Females outnumbered males (6:4) as reported in some text books. Details of patient data (including SCORTEN and mortality data) are given below [Tables 1 and 2]. Out of the ten patients, 5 had stopped probable offending drug themselves before reporting to us, but 2 of them died. In the remaining 5, probable offending drugs (mostly multiple) were stopped by us immediately on reporting.

Table 1: Clinical profile of patients

No	Age/sex	Time from the onset in days	Offending drug	Medical history	Category of ACDR
1	70/M	12	Antituberculous therapy	TB, DM	TEN
2	03/F	02	Phenytoin	--	SJS-TEN
3	12/M	10	Pyrimethamine+sulphamethoxypyridazine	--	TEN
4	35/F	03	Carbamazepine	--	SJS-TEN
5	19/F	02	Carbamazepine	--	TEN
6	45/F	01	Carbamazepine	DM, HTN, Bell's Palsy	TEN
7	38/M	08	Paracetamol	DM, TB	TEN
8	70/M	01	Furosemide	DM, HTN, CAD,	SJS-TEN
9	20/F	02	Rifampicin	TB	TEN
10	08/F	03	Carbamazepine	--	SJS-TEN

TB - Tuberculosis, DM - Diabetes mellitus, HTN - Hypertension, CAD - Coronary artery disease, ACDR - Adverse cutaneous drug reaction

Table 2: Patient data

No	Age (yrs)	BSA Involved		HR		BUN		BSL		HCO3		SCORTEN		Outcome (days)
		D1	D5	D1	D5	D1	D5	D1	D5	D1	D5			
1	70	40	70	↑	N	N	↑	↑	↑	N	↓	4	6	Dead 7 d
2	03	15	<10	↑	N	N	N	N	N	N	N	2	0	S
3	12	80	100	↑	↑	N	↑	↓	↑	↓	↓	3	4	Dead 5 d
4	35	20	30	N	N	N	N	N	N	N	N	2	1	S
5	19	30	20	↑	N	N	N	N	N	N	N	2	1	S
6	45	10	80	↑	↑	N	↑	↑	↑	N	↓	3	6	Dead 7 d
7	38	70	100	↑	↑	N	↑	↑	↑	N	↓	3	5	Dead 6 d
8	70	15	<10	↑	N	N	N	↑	↑	N	N	4	2	S
9	21	50	30	↑	N	N	N	N	N	N	N	2	1	S
10	08	20	15	↑	N	N	N	N	N	N	N	2	1	S

BSA - Body surface area, HR - Heart rate, BUN - Blood urea, BSL - Blood sugar level, D1 - Day 1, D5 - Day 5, S - Survived, ↑ - Rise, ↓ - Fall, N - Within normal range

Table 3: Mortality data

SCORTEN	No. of Pts		Expected Mortality (based on SCORTEN) %	Observed Mortality (based on SCORTEN) No. (%)	
	D1	D5		D1	D5
0-1	1	5	3	0 (0)	(00)
2	4	1	12	0 (0)	(00)
3	3	0	35	3 (100)	0 (0)
4	2	1	58	1 (50)	1 (100)
>5	-	3	90	-	3 (100)

DISCUSSION

After analyzing above data it is clear that none of the patients had malignancy but 4 out of 10 had pre-existing diabetes mellitus and 03 of them died. Tuberculosis was seen in 3 patients and 2 out of 3 died. Thus in Indian sub-continent probably these systemic diseases and other severe systemic illnesses need to be given weightage equal to malignancy. Age had no effect on the ultimate mortality but more male 3/4 died as compared to females 1/6. As is well known, ultimate cause of death was septicemia in all 4 cases who died, despite best possible management in a tertiary care hospital.

In SCORTEN analysis, % of BSA involvement entails 01 point, equal to other six parameters, however it is a well known fact (as observed in this study too) that BSA involvement of >40% had very poor prognosis. Therefore BSA involvement of >40% should be given more weightage as in burn scores.

Analysis of data given in Table numbers 02 and 03 reveals that patient number 1, 3, 5 and 6 who ultimately died had SCORTEN of either 3 or 4 on day 01 (these scores have a predicted mortality of 35 to 50%) and in all of them SCORTEN

increased to 5 or 6 on day 05 (at these scores prediction of mortality rate rises to more than 90%). Thus it is apparent that expected mortality based on SCORTEN of day 05 is more accurate than SCORTEN calculated on first day.

Though this study involves only 10 cases, following amendment are recommended keeping in mind the conditions prevalent in the Indian sub-continent. a) Percentage (%) of BSA involvement be given graded points e.g. 10-30% = 01 point, >30% = 02 points. b) Besides malignancy other systemic diseases like pre-existing diabetes mellitus, tuberculosis, cardiac disorders, other severe chronic diseases should also be included while calculating SCORTEN. c) SCORTEN analysis should be done on first as well as fifth day to get more accurate picture and prognosis.

Larger and longer studies are required to further authenticate and confirm these observations so that a modified and better SCORTEN may evolve.

REFERENCES

1. Bastuji-Garin S, Rzany B, Stern NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal Necrolysis, Stevens-Johnson syndrome and erythema multiforme. *Arch Dermatol* 1993;129:92-6.
2. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, *et al.* Medication use and the risk of Stevens-Johnson syndrome and toxic epidermal Necrolysis. *N Engl J Med* 1995;333:1600-7.
3. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, *et al.* Toxic epidermal Necrolysis: Clinical findings and prognostic factors in 87 patients. *Arch Dermatol* 1987;123:1160-5.
4. Bastuji-Garin S, Fouchard N, Bertochi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: A severity of illness score for toxic epidermal Necrolysis. *J Invest Dermatol* 2000;115:149-53.